Genetic Factors in Your Sleep Response to GLP-1 Therapy The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, and GIPR variants that relate to GLP-1 and related signaling pathways
The injectable obesity medications Semaglutide 2.4 mg, a selective GLP-1 receptor agonist, produces robust and durable weight loss of approximately 1516% over 68 weeks ( Tirzepatide, a dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonist, delivers even greater weight loss, exceeding 20% at the highest dose in pivotal trials ( Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, represents a further step in efficacy, with 24.2% weight loss achieved within 48 weeks in phase 2 studies ( Survodutide, an oxyntomodulin analogue, achieved clinically meaningful weight loss ( Table 2
Nutrabalance is an Australian first, offering daily nutritional support for your GLP-1 assisted health plan, through a range of supplement products
It is primarily found in your muscles and liver
